Why did Biotech Beat Pharma to Bring the First Gene Therapy to Market?
Pharma would seemingly best biotech in any competition. A few CEOs explain why it left the honor…
March 28, 2017 - 5 minutes
Genfit
Not to be Underestimated: What’s the Hype around NASH?
Since 2014, investment in Non-Alcoholic SteatoHepatitis (NASH) has taken off with a fervor reminiscent of…
February 7, 2017 - 10 minutes
The Largest Deals, Fundraising and Exits of 2016 in European Biotech
Curious about which technologies have attracted the most cash in biotech finance this year? Here's a…
December 26, 2016 - 5 minutes
Green Light for Genfit to Tackle another Liver Disease
The FDA has cleared Genfit's IND application to treat a second liver disease with a…
November 7, 2016 - 3 minutes
Genfit’s Non-Invasive Diagnostic could unlock the NASH Market
Genfit reinforced its leading place in the race to find a cure for NASH when…
September 20, 2016 - 2 minutes
Beyond NASH: Genfit jumps into another Critical Liver Condition
Genfit is extending the applications of its star candidate, Elafibranor, to a second liver disease -…
March 31, 2016 - 2 minutes
Genfit Has Enroled its First Patient in a NASH Phase III Trial
Genfit (France) has enroled their first patient in the highly anticipated phase III trial (RESOLVE-IT)…
March 11, 2016 - 2 minutes
10 Hot European Biotechs to watch in 2016
Looking forward to 2016, I wondered which Biotechs I would watch closely. Here's my list…
January 12, 2016 - 6 minutes
Infographic: The Anatomy of European Biotech
Which part of our body do European biotechs prefer to target? And how diversified are…
December 10, 2015 - 1 minute
Interview with the CEO of Genfit – The Billion Euro Liver Biotech on its phase III NASH Drug
Interview with Jean-François Mouney (Chairman and CEO of Genfit) at the 'Liver Meeting 2015' congress…
November 16, 2015 - 5 minutes
Boehringer kindles NASH treatments with Pharmaxis’ drug acquisition
Does NASH mean anything to you? You should be vigilant about this market as it could…
May 19, 2015 - 4 minutes
